NCT06215222 Capsule Microbiota Sampling in IBS/Functional Gastrointestinal Disease
| NCT ID | NCT06215222 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Stanford University |
| Condition | IBS - Irritable Bowel Syndrome |
| Study Type | OBSERVATIONAL |
| Enrollment | 40 participants |
| Start Date | 2023-11-16 |
| Primary Completion | 2025-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 40 participants in total. It began in 2023-11-16 with a primary completion date of 2025-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
We will sample intestinal microbiota using a microbiome sampling capsule in Healthy, Irritable Bowel Syndrome (IBS), and Functional Gastrointestinal Disease.
Eligibility Criteria
Inclusion Criteria: * Males or females 18 years of age or older and 70 years of age or younger at the time of the first Screening Visit. * American Society of Anesthesiologists (ASA) Physical Status Classification System 1 or 2 (1-A normal healthy patient or 2-A patient with mild systemic disease) * For women of childbearing potential, negative urine pregnancy test within 7 days of Screening Visit. Willingness to use highly effective contraception during the entire study period (e.g.: implants, injectables, oral contraceptives, intra-uterine device or declared abstinence). * Subject is fluent in English and understands the study protocol and informed consent and is willing and able to comply with study requirements and sign the informed consent form. * Positive for at least one clinical symptoms consistent with SIBO and or IBS and or a Rome Diagnosis of functional GI disorder (Rome IV criteria) Exclusion Criteria: * History of any of the following: * Prior gastric or esophageal surgery, including lap banding or bariatric surgery * Bowel obstruction * Gastric outlet obstruction * Diverticulitis * Inflammatory bowel disease * Ileostomy or colostomy * Gastric or esophageal cancer * Achalasia * Esophageal diverticulum * Active Dysphagia or Odynophagia * Active medication use for any gastrointestinal conditions * Pregnancy or planned pregnancy within 30 days from Screening Visit, or breast-feeding * Any form of active substance abuse or dependence (including drug or alcohol abuse), unstable medical or psychiatric disorder, or any chronic condition susceptible, in the opinion of the investigator, to interfere with the conduct of the study
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06215222 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying IBS - Irritable Bowel Syndrome. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06215222 currently recruiting?
Yes, NCT06215222 is actively recruiting participants. Contact the research team at seanspen@stanford.edu for enrollment information.
Where is the NCT06215222 trial being conducted?
This trial is being conducted at Redwood City, United States.
Who is sponsoring the NCT06215222 clinical trial?
NCT06215222 is sponsored by Stanford University. The trial plans to enroll 40 participants.